stockrowAlnylam Pharmaceuticals, Inc. (ALNY) vs Exelixis, Inc. (EXEL)
- Alnylam Pharmaceuticals, Inc. ALNY 156.74 +0.05%
- Exelixis, Inc. EXEL 69.32 +0.89%
Alnylam Pharmaceuticals, Inc. and Exelixis, Inc. are both Biotechnology companies. Alnylam Pharmaceuticals, Inc. is the larger, with a market value of $21.0B against $16.8B — 1.3× the size. Alnylam Pharmaceuticals, Inc. trades at the lower P/E: 7.9× against 19.9×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against 9.12%. Alnylam Pharmaceuticals, Inc. has the higher net margin (52.9% vs 35.5%) and the lower return on invested capital (59.4% vs 66.6%). Across the 22 metrics below, Alnylam Pharmaceuticals, Inc. leads on 12 and Exelixis, Inc. on 10.
Valuation
Profitability
| Metric | ALNY | EXEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 77.28% | 96.26% | 65.16% |
| Operating margin | 19.50% | 40.19% | 0.00% |
| Net margin | 52.85% | 35.45% | 0.00% |
| Free cash flow margin | 16.08% | 45.84% | 0.00% |
| Return on equity | 138.07% | 44.32% | (50.12%) |
| Return on assets | 41.25% | 33.17% | (45.60%) |
| Return on invested capital | 59.37% | 66.59% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack